The call highlighted significant progress in Vistagen's clinical programs and strategic pipeline expansion, showing strong potential for future success. However, increased R&D expenses and net loss, along with site termination challenges, pose concerns.

Company Guidance -

Q2 2026

During Vistagen Therapeutics' Fiscal Year 2026 First Quarter Corporate Update call, the company provided several key metrics regarding its progress and future plans. For the quarter ending June 30, 2025, research and development expenses were $11.7 million, up from $7.6 million in the previous year, reflecting ongoing investments in the PALISADE program. General and administrative expenses were $4.4 million, slightly lower than the $4.6 million from the same period last year. The net loss attributable to common stockholders was $15.1 million, compared to $10.7 million the previous year. The company reported $63.2 million in cash, cash equivalents, and marketable securities as of June 30, 2025. Vistagen anticipates reporting top-line data from its PALISADE-3 Phase III trial in Q4 2025, with PALISADE-4 results expected in the first half of 2026. These trials are critical for the potential U.S. new drug application submission for fasedienol for treating social anxiety disorder.

Advancement of Late Phase III Clinical Programs

Vistagen's intranasal fasedienol is advancing in late Phase III development for social anxiety disorder (SAD) with potential top-line data from the PALISADE-3 trial expected in Q4 2025, and PALISADE-4 results expected in the first half of 2026.

Strategic Pipeline Expansion

Vistagen is advancing further Phase II development of Itruvone for major depressive disorder and PH80 for menopausal hot flashes, with a U.S. IND submission for PH80 expected in Q4 2025.

Strong Financial Position

As of June 30, 2025, Vistagen reported $63.2 million in cash, cash equivalents, and marketable securities.

Positive Open Label Extension Study Results

High conversion rates to open-label extension study with 80%+ of subjects continuing, indicating promising engagement and retention for fasedienol.

VistaGen Therapeutics (VTGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VTGN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2026 (Q2)	-0.47 / -	-0.42	―	―	―
Aug 07, 2025	2026 (Q1)	-0.47 / -0.47	-0.35	-34.29% (-0.12)	―
Jun 17, 2025	2025 (Q4)	-0.50 / -0.43	0.3	-243.33% (-0.73)	―
Feb 13, 2025	2025 (Q3)	-0.51 / -0.46	-0.22	-109.09% (-0.24)	―
Nov 07, 2024	2025 (Q2)	-0.39 / -0.42	-0.66	36.36% (+0.24)	―
Aug 13, 2024	2025 (Q1)	-0.40 / -0.35	-0.94	62.77% (+0.59)	―
Jun 11, 2024	2024 (Q4)	-0.36 / 0.30	-1.61	118.63% (+1.91)	―
Feb 13, 2024	2024 (Q3)	-0.30 / -0.22	-1.5	85.33% (+1.28)	―
Nov 09, 2023	2024 (Q2)	-0.68 / -0.66	-2.4	72.50% (+1.74)	―
Aug 10, 2023	2024 (Q1)	-0.86 / -0.94	-3	68.67% (+2.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VTGN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$2.73	$2.97	+8.79%
Jun 17, 2025	$2.38	$2.06	-13.45%
Feb 13, 2025	$2.85	$2.97	+4.21%
Nov 07, 2024	$3.12	$3.14	+0.64%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vistagen Therapeutics Inc. (VTGN) report earnings?

Vistagen Therapeutics Inc. (VTGN) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Vistagen Therapeutics Inc. (VTGN) earnings time?

Vistagen Therapeutics Inc. (VTGN) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VTGN EPS forecast?

VTGN EPS forecast for the fiscal quarter 2026 (Q2) is -0.48.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing